Market Currents
QIAGEN (QGEN) says it's received FDA approval to market its therascreen KRAS test to provide...
-
Friday, July 6, 2012, 4:38 PM ETQIAGEN (QGEN) says it's received FDA approval to market its therascreen KRAS test to provide guidance on the use of Erbitux as a treatment in patients with metastatic colorectal cancer.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
